⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ELDN News
Eledon Pharmaceuticals, Inc. Common Stock
A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up
prnewswire.com
ELDN
VRTX
VKTX
The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy
prnewswire.com
SANA
ELDN
VRTX
NCEL
NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes
globenewswire.com
NCEL
ELDN
Form 8-K
sec.gov
ELDN
Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus
globenewswire.com
ELDN
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine
globenewswire.com
ELDN
Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions
globenewswire.com
ELDN
NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes
globenewswire.com
NCEL
ELDN
Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress
globenewswire.com
ELDN
Form 8-K
sec.gov
ELDN